An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- For Dose Escalation:

- Subjects with any previously treated advanced (metastatic or refractory) solid
tumor type and B-cell non-Hodgkin lymphoma

- For Cohort Expansion:

- Subjects must have a previously treated advanced solid tumor or B cell
non-Hodgkin's lymphoma to be eligible

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- For certain subjects, willing and able to provide pre-treatment and on-treatment
fresh tumor biopsy

- Women of child-bearing potential and men must use an acceptable method of
contraception during treatment and for 23 weeks after treatment for women and 31
weeks for men

Exclusion Criteria:

- Known central nervous system metastases or central nervous system as the only source
of disease

- Other concomitant malignancies (with some exceptions per protocol)

- Active, known or suspected autoimmune disease

- Uncontrolled or significant cardiovascular disease

- History of hepatitis (B or C)

- History of active or latent tuberculosis